AU2017323868A1 - Lysine specific histone demethylase-1 inhibitors and uses therefor - Google Patents

Lysine specific histone demethylase-1 inhibitors and uses therefor Download PDF

Info

Publication number
AU2017323868A1
AU2017323868A1 AU2017323868A AU2017323868A AU2017323868A1 AU 2017323868 A1 AU2017323868 A1 AU 2017323868A1 AU 2017323868 A AU2017323868 A AU 2017323868A AU 2017323868 A AU2017323868 A AU 2017323868A AU 2017323868 A1 AU2017323868 A1 AU 2017323868A1
Authority
AU
Australia
Prior art keywords
lsd1
isolated
proteinaceous molecule
pct
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017323868A
Other languages
English (en)
Inventor
Peter MILBURN
Sudha RAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epiaxis Therapeutics Pty Ltd
Original Assignee
Epiaxis Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903602A external-priority patent/AU2016903602A0/en
Application filed by Epiaxis Therapeutics Pty Ltd filed Critical Epiaxis Therapeutics Pty Ltd
Publication of AU2017323868A1 publication Critical patent/AU2017323868A1/en
Assigned to EPIAXIS THERAPEUTICS PTY LTD reassignment EPIAXIS THERAPEUTICS PTY LTD Request for Assignment Assignors: UNIVERSITY OF CANBERRA
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13Tumour cells, irrespective of tissue of origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083Miscellaneous (1.14.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y114/00Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99Miscellaneous (1.14.99)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017323868A 2016-09-07 2017-09-07 Lysine specific histone demethylase-1 inhibitors and uses therefor Abandoned AU2017323868A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016903602A AU2016903602A0 (en) 2016-09-07 Inhibitors and uses therefor
AU2016903602 2016-09-07
PCT/AU2017/050969 WO2018045422A1 (en) 2016-09-07 2017-09-07 Lysine specific histone demethylase-1 inhibitors and uses therefor

Publications (1)

Publication Number Publication Date
AU2017323868A1 true AU2017323868A1 (en) 2019-03-21

Family

ID=61561256

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017323868A Abandoned AU2017323868A1 (en) 2016-09-07 2017-09-07 Lysine specific histone demethylase-1 inhibitors and uses therefor

Country Status (8)

Country Link
US (1) US20220040280A1 (enExample)
EP (1) EP3509627A4 (enExample)
JP (1) JP2019534317A (enExample)
CN (1) CN110312522A (enExample)
AU (1) AU2017323868A1 (enExample)
CA (1) CA3035806A1 (enExample)
SG (1) SG11201901624RA (enExample)
WO (1) WO2018045422A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102095104B1 (ko) * 2018-04-24 2020-04-23 서울대학교산학협력단 PKCα-LSD1-NFκB 경로를 표적으로 하는 염증반응 조절제 스크리닝 방법용도
EP3636284A1 (en) * 2018-10-11 2020-04-15 NBE Therapeutics AG Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
CN110142068B (zh) * 2019-06-12 2024-02-02 杭州华得森生物技术有限公司 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法
US12429477B2 (en) 2019-09-03 2025-09-30 The Council Of The Queensland Institute Of Medical Research Methods and agents for determining patient status
CN112326961B (zh) * 2020-10-30 2021-08-06 福州迈新生物技术开发有限公司 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备
WO2023067058A1 (en) * 2021-10-20 2023-04-27 Queen Mary University Of London Sequential treatments and biomarkers to reverse resistance to kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2591717A1 (en) * 2004-12-16 2006-07-06 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog lsd1
US7858395B2 (en) * 2005-07-13 2010-12-28 Universitaetsklinikum Freiburg Antibodies for use in identifying and/or scoring prostate cancer and androgen receptor-dependent gene expression control
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US20120108500A1 (en) * 2010-10-07 2012-05-03 Naoki Sakane Compositions and Methods for Modulating Immunodeficiency Virus Transcription
EP2906602B1 (en) * 2012-10-12 2019-01-16 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
CA2916533C (en) * 2013-06-25 2022-12-20 University Of Canberra Methods and compositions for modulating cancer stem cells
US9186391B2 (en) * 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
EP3185858A4 (en) * 2014-08-25 2017-12-27 University of Canberra Compositions for modulating cancer stem cells and uses therefor
JP2019500394A (ja) * 2015-12-30 2019-01-10 ノバルティス アーゲー 有効性が増強された免疫エフェクター細胞治療

Also Published As

Publication number Publication date
CN110312522A (zh) 2019-10-08
CA3035806A1 (en) 2018-03-15
US20220040280A1 (en) 2022-02-10
JP2019534317A (ja) 2019-11-28
EP3509627A4 (en) 2020-05-06
WO2018045422A1 (en) 2018-03-15
EP3509627A1 (en) 2019-07-17
SG11201901624RA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
US20220040280A1 (en) Inhibitors and uses thereof
AU2015309686B2 (en) Compositions for modulating cancer stem cells and uses therefor
US20210121496A1 (en) Methods and compositions for modulating cancer stem cells
CN112204047A (zh) Pd-l1结合黏合素及与其相关的用途
EP2397148A2 (en) Compositions and methods for the treatment of ophthalmic disease
US10736892B2 (en) Stem cell modulation II
US20190002527A1 (en) Methods and compositions for the inhibition of trpv4
CA3204415A1 (en) Modified mir-135, conjugated form thereof, and uses of same
CN118251406A (zh) 血管活性肠肽(vip)受体拮抗剂
US20140288010A1 (en) Compositions and Methods for Increasing Stem Cell Survival
CA3026154A1 (en) Mobilizing agents and uses therefor
WO2024151501A1 (en) Novel imidazopyrimidine compound and uses thereof
CN116546998A (zh) 葡萄糖调节化合物、其组合物和其用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: EPIAXIS THERAPEUTICS PTY LTD

Free format text: FORMER APPLICANT(S): UNIVERSITY OF CANBERRA

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application